by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
Financial Patient Assistance Programs for MPNs
by Lou Ann Donovan The World Health Organization (WHO) published a revised document in 2008 listing MPNs as a blood cancer to promote the recognition of the genetic characterization of myeloid malignancies. Now, there are numerous organizations providing financial support and assistance with travel to a cancer center, copay and medication assistance, and many programs […]
Patients are Asking – MPN Expert Dr. Prithviraj Bose
Episode 1 of 3 in Patients are Asking Series What symptoms should I look for to see if I might be progressing from polycythemia vera to myelofibrosis? When would you typically recommend Next Generation Sequencing (NGS) and what are the benefits? Why does bone & joint pain occur and what are some possible solutions? Dr. […]
David’s Push for an MPN Specialist – A Polycythemia Vera (PV) Story
download Key Points: See an MPN Specialist Learn about your MPN Become your own advocate Shared decision making has become the norm Prepare questions for your doctor’s appointment A Clinical Trial may be your best option Seek support from knowledgeable patients on Facebook groups and other online resources Thank you to LLS for conducting this […]
Being an MPN Patient in COVID-19 Era: The Mytico Study
Introduction: The Coronavirus disease 2019 (COVID-19) pandemic and the resulting social distancing, determined a reduction in access to care and limitations of individual freedom, with a consequent strong impact on quality of life (QoL), anxiety levels and medical management of onco-hematological people. In particular, in the case of patients with chronic myeloproliferative neoplasm (MPN), concern […]
Michael’s MPN Story
by Michael Movsky My MPN journey began at the hematologist’s office on a pleasant March day in 2018, when she confirmed a diagnosis of Essential Thrombocytosis (ET) through various factors, including the detection of the JAK 2 mutation…at which point I was handed an informational booklet on the topic from the Leukemia and Lymphoma Society. […]
Inflammatory Microenvironment & Specific T-Cells in MPNs
Abstract The Philadelphia-negative myeloproliferative neoplasms (MPNs) are malignancies of the hematopoietic stem cell (HSC) arising as a consequence of clonal proliferation driven by somatically acquired driver mutations in discrete genes (JAK2, CALR, MPL). In recent years, along with the advances in molecular characterization, the role of immune dysregulation has been achieving increasing relevance in the […]
Covid-19 Vaccines FAQs for Patients and Caregivers
The Leukemia & Lymphoma Society (LLS) hears from blood cancer patients and caregivers each day about the profound effects of the pandemic on their cancer care and daily lives. While it’s been an incredibly trying time, there are bright spots ahead as we all celebrate FDA authorization of two COVID-19 vaccines and look toward more safe, effective vaccines on […]
Precision Medicine and Gene Mutations in MPNs
by David Wallace What does precision medicine look like in MPNs? Can it be used to diagnose, prognosticate and treat patients? Discover information on driver mutations, symptom burden scoring and how it is used in some clinical visits. Learn more as Dr. Naveen Pemmaraju, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University […]
New MPN Drug Treatments in Development
by David Wallace What are some of the latest combination drug treatments in development for MPN? Find out the latest on combination add-on strategies to JAK inhibitors and other new agents. Two combination therapies for Myelofibrosis look promising as they move into phase 3 clinical trials. They include adding CPI-0610 (a bromodomain, BET, inhibitor) and […]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 21
- Next Page »
